<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733588</url>
  </required_header>
  <id_info>
    <org_study_id>XSGO-PB01</org_study_id>
    <secondary_id>1R44DK107114-01</secondary_id>
    <nct_id>NCT02733588</nct_id>
  </id_info>
  <brief_title>Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients</brief_title>
  <official_title>A Phase 2 Proof-of-Concept Study of Sensor-Guided, Clinician-Administered Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Post-Prandial Hypoglycemia in Post-Bariatric Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test an optimized control system for sensor-guided
      (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical
      setting in patients with severe hypoglycemia following bariatric surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, single-center, open-label, proof-of-concept study designed to test the
      ability of the control algorithm to detect and direct timing of G-Pump™ glucagon infused from
      an OmniPod® pump to prevent hypoglycemia in patients with post-bariatric hypoglycemia
      syndrome. While the algorithm will provide an alert as to when glucagon should be dosed to
      prevent hypoglycemia, there will be no automation in this clinical trial and it will
      ultimately be up to the physician to initiate dosing via the OmniPod® controller.

      Participant on continuous glucose monitoring will arrive at the clinic and IV line will be
      inserted for venous access. Subject will then be asked to drink a liquid mixed meal
      containing 60 g of carbohydrates, e.g. Boost® Nutritional Drink, over 10 minutes. Blood
      samples will be collected for glucose and hormone measurement.

      The open-loop system will be set to recognize low sensor glucose values, triggering an alert
      to the physician, who will deliver a bolus of 150 or 300 µg of glucagon via the pump, with
      the goal of preventing further decline in glucose values. Depending on response, a second
      bolus dose of 150 or 300 µg of glucagon may be administered. Plasma glucose will be measured
      after glucagon administration to ensure successful treatment and glucose stability, and
      glucagon levels will be analyzed concurrently to determine magnitude of increase above
      baseline. Sensors will be downloaded for subsequent analysis of appropriateness of alert
      timing and trigger for glucagon bolus delivery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection/Notification of Hypoglycemia</measure>
    <time_frame>0 - 120 minutes following dosing</time_frame>
    <description>Frequency with which the device controller software correctly identifies impending hypoglycemia (glucose &lt; 75 mg/dl) and notifies the investigator to initiate treatment. Reported as the number of successful identifications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Severe Hypoglycemia</measure>
    <time_frame>0 - 120 minutes following dosing</time_frame>
    <description>Frequency of severe hypoglycemia defined as glucose levels below 60 mg/dl. Reported as the number of subjects with severe hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Rebound Hyperglycemia</measure>
    <time_frame>0 - 120 minutes following dosing</time_frame>
    <description>Frequency of rebound hyperglycemia defined as glucose levels above 180 mg/dl. Reported as the number of subjects with rebound hyperglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Time in Range</measure>
    <time_frame>0 - 120 minutes following dosing</time_frame>
    <description>Time glucose remains in goal range, 60-180 mg/dl, reported in minutes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Complications of Bariatric Procedures</condition>
  <arm_group>
    <arm_group_label>G-Pump™ (glucagon infusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pump™ (glucagon infusion)</intervention_name>
    <description>0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump</description>
    <arm_group_label>G-Pump™ (glucagon infusion)</arm_group_label>
    <other_name>glucagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with ongoing post-bariatric hypoglycemia with prior episodes of
             neuroglycopenia, unresponsive to dietary intervention (low glycemic index, controlled
             carbohydrate portions) and trial of acarbose therapy at the maximally tolerated dose.

          -  willingness to provide informed consent and follow all study procedures, including
             attending all scheduled visits.

        Exclusion Criteria:

          -  documented hypoglycemia occurring in the fasting state (&gt; 12 hours fast);

          -  chronic kidney disease stage 4 or 5;

          -  hepatic disease, including serum alanine aminotransferase or aspartate
             aminotransferase greater than or equal to 3 times the upper limit of normal; hepatic
             synthetic insufficiency as defined as serum albumin &lt; 3.0 g/dL; or serum bilirubin &gt;
             2.0;

          -  congestive heart failure, New York Heart Association class II, III or IV;

          -  history of myocardial infarction, unstable angina or revascularization within the past
             6 months;

          -  history of a cerebrovascular accident;

          -  seizure disorder (other than with suspect or documented hypoglycemia);

          -  active treatment with any diabetes medications except for acarbose;

          -  active malignancy, except basal cell or squamous cell skin cancers;

          -  personal or family history of pheochromocytoma or disorder with increased risk of
             pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease);

          -  known insulinoma;

          -  major surgical operation within 30 days prior to screening;

          -  hematocrit ≤ 33%;

          -  bleeding disorder, treatment with warfarin, or platelet count &lt;50,000;

          -  blood donation (1 pint of whole blood) within the past 2 months;

          -  active alcohol abuse or substance abuse;

          -  current administration of oral or parenteral corticosteroids;

          -  pregnancy and/ or Lactation: For women of childbearing potential: there is a
             requirement for a negative urine pregnancy test and for agreement to use contraception
             during the study and for at least 1 month after participating in the study.

          -  use of an investigational drug within 30 days prior to screening.

          -  there will be no involvement of special vulnerable populations such as pregnant women,
             prisoners, institutionalized or incarcerated individuals, or others who may be
             considered vulnerable populations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <results_first_submitted>August 21, 2018</results_first_submitted>
  <results_first_submitted_qc>October 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2018</results_first_posted>
  <last_update_submitted>October 28, 2018</last_update_submitted>
  <last_update_submitted_qc>October 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypoglycemia</keyword>
  <keyword>glucagon</keyword>
  <keyword>glucose metabolism disorders</keyword>
  <keyword>hormones</keyword>
  <keyword>gastrointestinal agents</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>incretins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT02733588/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT02733588/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 8 patients were enrolled in the study. One subject withdrew prior to completing study procedures, leaving 7 subjects who were assigned to a treatment arm. Consistent with the number of subjects who started treatment period 1, the number enrolled is given as 7 even though demographics are presented for all 8 qualified/enrolled subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-Pump™ (Glucagon Infusion)</title>
          <description>0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
G-Pump™ (glucagon infusion): 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 8 subjects were enrolled into the study and demographic characteristics are provided for these 8 subjects. One subject dropped out before receiving study treatment or beginning any study procedures. A total of 7 unique subjects received treatment, and due to the iterative nature of the study, 2 subjects participated twice.</population>
      <group_list>
        <group group_id="B1">
          <title>G-Pump™ (Glucagon Infusion)</title>
          <description>0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
G-Pump™ (glucagon infusion): 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="38" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Months postop hypoglycemia diagnosed</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="12" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Months postop at study visit</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116" lower_limit="45" upper_limit="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" lower_limit="5.4" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" lower_limit="37.8" upper_limit="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" lower_limit="24.3" upper_limit="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Delta BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-16.3" lower_limit="-36.7" upper_limit="-5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prescribed glucose-modifying medications</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Received nutritional counseling</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Detection/Notification of Hypoglycemia</title>
        <description>Frequency with which the device controller software correctly identifies impending hypoglycemia (glucose &lt; 75 mg/dl) and notifies the investigator to initiate treatment. Reported as the number of successful identifications.</description>
        <time_frame>0 - 120 minutes following dosing</time_frame>
        <population>Includes all subjects who completed a study visit, including repeat visits by 2 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pump™ (Glucagon Infusion)</title>
            <description>0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
G-Pump™ (glucagon infusion): 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump</description>
          </group>
        </group_list>
        <measure>
          <title>Detection/Notification of Hypoglycemia</title>
          <description>Frequency with which the device controller software correctly identifies impending hypoglycemia (glucose &lt; 75 mg/dl) and notifies the investigator to initiate treatment. Reported as the number of successful identifications.</description>
          <population>Includes all subjects who completed a study visit, including repeat visits by 2 subjects.</population>
          <units>successful events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Severe Hypoglycemia</title>
        <description>Frequency of severe hypoglycemia defined as glucose levels below 60 mg/dl. Reported as the number of subjects with severe hypoglycemia.</description>
        <time_frame>0 - 120 minutes following dosing</time_frame>
        <population>Includes all subjects who completed a study visit, including repeat visits by 2 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pump™ (Glucagon Infusion)</title>
            <description>0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
G-Pump™ (glucagon infusion): 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Severe Hypoglycemia</title>
          <description>Frequency of severe hypoglycemia defined as glucose levels below 60 mg/dl. Reported as the number of subjects with severe hypoglycemia.</description>
          <population>Includes all subjects who completed a study visit, including repeat visits by 2 subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Rebound Hyperglycemia</title>
        <description>Frequency of rebound hyperglycemia defined as glucose levels above 180 mg/dl. Reported as the number of subjects with rebound hyperglycemia.</description>
        <time_frame>0 - 120 minutes following dosing</time_frame>
        <population>Includes all subjects who completed a study visit, including repeat visits by 2 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pump™ (Glucagon Infusion)</title>
            <description>0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
G-Pump™ (glucagon infusion): 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Rebound Hyperglycemia</title>
          <description>Frequency of rebound hyperglycemia defined as glucose levels above 180 mg/dl. Reported as the number of subjects with rebound hyperglycemia.</description>
          <population>Includes all subjects who completed a study visit, including repeat visits by 2 subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Time in Range</title>
        <description>Time glucose remains in goal range, 60-180 mg/dl, reported in minutes</description>
        <time_frame>0 - 120 minutes following dosing</time_frame>
        <population>Includes all subjects who completed a study visit, including repeat visits by 2 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pump™ (Glucagon Infusion)</title>
            <description>0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
G-Pump™ (glucagon infusion): 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Time in Range</title>
          <description>Time glucose remains in goal range, 60-180 mg/dl, reported in minutes</description>
          <population>Includes all subjects who completed a study visit, including repeat visits by 2 subjects.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected from enrollment until 1 day following the last study visit. Thus the total monitored period was approximately 1 month per patient.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>G-Pump™ (Glucagon Infusion)</title>
          <description>0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
G-Pump™ (glucagon infusion): 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia, post-discharge</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infusion site edema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infusion site discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bleeding from catheter site upon pump removal</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size was small; gender mix, although unequal, is typical of the PBH population at Joslin. The protocol was modified at every stage to test iterations of the detection algorithm and/or increasing glucagon doses to prevent hypoglycemia.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mary-Elizabeth Patti, MD</name_or_title>
      <organization>Joslin Diabetes Center</organization>
      <phone>617-309-2665</phone>
      <email>mary.elizabeth.patti@joslin.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

